FDA approved Casgevy, first CRISPR/Cas9 gene-editing therapy
Dated 8 December 2023: FDA approved Casgevy, first CRISPR/Cas9 gene-editing therapy. In the causal graph this event strengthens the driver Biotechnology Innovation.
Who was responsible
Contribution type and responsibility level for each recorded actor — not sole-author shorthand.
No public contributors are listed for this fact.
What changed
Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.
- FactFDA approved Casgevy, first CRISPR/Cas9 gene-editing therapy
- strengthensDriverBiotechnology Innovation
provisional weight · verified
Causal path
How this event connects to drivers and indicators in the graph.
- FactFDA approved Casgevy, first CRISPR/Cas9 gene-editing therapy
- strengthensDriverBiotechnology Innovation
Cite this page
Factrail. (2026). FDA approved Casgevy, first CRISPR/Cas9 gene-editing therapy. Factrail. https://factrail.ai/facts/fda-casgevy-first-crispr-gene-editing-therapy-2023
https://factrail.ai/facts/fda-casgevy-first-crispr-gene-editing-therapy-2023
Accessed 15 October 2026.
By the Factrail desk · Method: how we source and score · Last reviewed
Dispute this factNamed here, or represent someone who is? Request a right of reply.